Gossamer Bio Q3 net loss $48.2M; PROSERA topline due Feb 2026

Gossamer Bio, Inc.

2025-Q3 EPS reported -$0.54 revenue$34,672,000

Net loss of $48.2M ($0.21 per share) vs $30.8M loss a year ago; revenue from Chiesi collab $13.3M.
Cash, cash equivalents and marketable securities $180.2M; sufficient to fund ops into 2027.
PROSERA Phase 3 PAH study enrollment complete (390 pts); topline results expected February 2026.
First site activated for SERANATA Phase 3 PH-ILD study; targeting enrollment of ~480 patients.
Strategic option agreement to acquire Respira via 1.5M shares; no new trials expected before 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.